Please login to the form below

Not currently logged in
Email:
Password:

Opko

This page shows the latest Opko news and features for those working in and with pharma, biotech and healthcare.

Versartis crashes as VELOCITY trial veers off track

Versartis crashes as VELOCITY trial veers off track

It’s not the first long-acting hGH to miss the mark in trials - earlier this year Pfizer and Opko’s once-weekly candidate also failed a phase III trial.

Latest news

  • Pfizer/Opko's long-acting growth hormone misses mark in trial Pfizer/Opko's long-acting growth hormone misses mark in trial

    Pfizer/Opko's long-acting growth hormone misses mark in trial. Previously forecast as a blockbuster product, hGH-CTP fails to show significant change. ... Pfizer and partner Opko ended 2016 on a disappointing note after their long-acting drug for growth

  • Pfizer buys majority stake in Redvax Pfizer buys majority stake in Redvax

    No financial details of the deal have been disclosed. This rounds off a busy M&A period for Pfizer which just a fortnight ago partnered with Opko Health on a late

  • RNA interference rebirth RNA interference rebirth

    TTR. TTR-mediated amyloidosis. I. TKM-ApoB. Tekmira. ApoB. hypercholesterolaemia. Stalled. bevasiranib. Opko Health.

  • Flicking the switch

    Opko Health is developing bevasiranib for the treatment for wet age-related macular degeneration (AMD). ... In phase II trials, bevasiranib inhibited the growth of choroidal neovascularisation and Opko have now initiated a pivotal phase III trial that

  • Mastering the gene

    Acuity plans to initiate its phase III programme in 2007 and in March the company agreed a merger with several partners to establish a publicly-traded company, Opko. ... If the trial goes as hoped, Opko may lead the race to reach the market with a siRNA

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch May 2016 Deal Watch May 2016

    The manufacturing CRLs have been out in force and AstraZeneca is not the only company on the receiving end with OPKO receiving a CRL earlier in the year [March] in relation ... 293. OPKO Health/ Vifor Fresenius. Licence. Rayaldee in EP, CA, Mexico,

  • Pharma deals in June 2015 Pharma deals in June 2015

    Opko's strategy in its $1.47bn acquisition of Bio-Reference Laboratories at $52.58 per share (approximately 60% premium) is to gain access to a range of diagnostic capabilities including ... Acquisition - company. 2, 050. Bio-Reference Laboratories/ OPKO

  • Pharma deals during December 2014 Pharma deals during December 2014

    This product, named hGH-CTP, was in the portfolio of Prolor Biotech which Opko acquired in August 2013 for $480m. ... The upfront payment of $295m from Pfizer will go some of the way to recoup the price Opko paid for Prolor.

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Collaboration, licence. 581. Opko Health / Pfizer. Long-acting hGH-CTP for growth hormone deficiency in adults and children (p3).

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics